ArticleUrologic oncology2025
A retrospective analysis of tissue, liquid, and germline testing in Hispanic and non-Hispanic men with advanced hormone-sensitive prostate cancer.
Article in Urologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionProstate cancer (PCa) is a major cause of cancer mortality among American men, with significant racial and ethnic disparities. Hispanic Americans (HAs) are underrepresented in PCa genomic studies despite comprising a large portion of cancer diagnoses. By comparing the frequency of common PCa mutations between HA and non-Hispanics (NHs), we aim to continue understanding the drivers of disparities in this underrepresented population.
methodsWe retrospectively analyzed 111 metastatic prostate adenocarcinoma patients with 313 tissue, liquid, and germline genomic sample results from patient blood at the University of Arizona Cancer Center (2015-2023). Patients were categorized by ethnicity into HAs and NHs. We assessed de-identified demographic, pathological, clinical, and genomic data. Continuous and categorical variables determined statistical significance were evaluated using t-tests or Kruskal-Wallis Rank sum tests and Chi-square or Fisher's exact tests, respectively (P < 0.05). Time-to-event data was analyzed using Kaplan-Meier Methods.
resultsOf the 111 patients included HAs represented 41%. HAs had higher median PSA levels at the time of diagnosis (148.5 ng/ml vs. 52.6 ng/ml, P = 0.024), more advanced pathological disease stages, including T4 (36% vs. 15%), and M1c (37.8% vs. 13.6%), less time to first-line treatment (1 vs 2 months, P ≤ 0.01), and higher median survival time from first-line to second-line treatment (23 vs 13 months, P < 0.01). TMPRSS2-ERG fusion and TMB-High (>10) mutations were more common in HAs (36% vs. 6%, P = 0.0009; 20% vs. 3%, P = 0.003).
conclusionOur study shows a more advanced clinical presentation of HAs PCa compared to NHs. Furthermore, significant genomic differences in PCa between HAs and NHWs, particularly in TMPRSS2-ERG fusion and TMB-High mutations, highlight the need for early detection and personalized treatment options. Addressing treatment disparities and expanding genomic research in HAs are crucial for developing effective interventions in this underrepresented population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.